Swiss Insurers Split on Coverage for Expensive Pancreatic Cancer Medication

Swiss health insurance companies are issuing conflicting decisions regarding cost coverage for Rasonque, a new pancreatic cancer drug manufactured by the US firm Revolution Medicines. Because the drug was approved in the United States in August 2026 but remains unapproved by Swiss regulatory authorities, health insurers must evaluate reimbursement requests on an individual, case-by-case basis.

Documents obtained by French-language public broadcaster RTS reveal divergent outcomes for patients with identical diagnoses at Lausanne University Hospital. On 27 October 2026, the health insurer Concordia agreed to cover the monthly cost of 39,800 dollars for one patient over a 12-month period. Two days later, on 29 October 2026, a third insurer refused coverage for another patient at the same facility, even though the medical justification rested on the same grounds.

In the case of the rejection, the insurer's advisory physician acknowledged that the high therapeutic benefit of the treatment was sufficiently proven in that specific case. However, the insurance company stated in its decision that it was unable to agree on an acceptable price with Revolution Medicines despite direct discussions with the manufacturer.

In another instance, a 63-year-old cancer patient in Geneva had three consecutive requests for Rasonque denied by her insurer, with the final rejection issued in September 2026. Her health insurance provider stated that the expected therapeutic benefit was not adequately demonstrated and noted that the manufacturer could not participate in co-financing the treatment costs.

The medication, generic name Daraxonrasib, targets specific advanced forms of pancreatic cancer and carries a price tag of approximately 40,000 Swiss francs per month in the United States. While some oncologists report that the treatment offers improvements in both life expectancy and quality of life, patients whose applications were turned down continue to rely on conventional chemotherapy treatments.

Written by Christiane Hofreiter christiane.hofreiter@alpineweekly.com